PMID- 31150165
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 8
IP  - 8
DP  - 2019 Jul
TI  - Comparison of PD-L1 detection assays and corresponding significance in evaluation 
      of diffuse large B-cell lymphoma.
PG  - 3831-3845
LID - 10.1002/cam4.2316 [doi]
AB  - The expression of programmed cell death ligand 1 (PD-L1) is a biomarker for 
      immunotherapy, but approved detection method is absent in diffuse large B-cell 
      lymphoma (DLBCL). Here, we performed three methods including immunohistochemistry 
      (IHC) (clone SP263 and SP142), RNAscope, and fluorescence in situ hybridization 
      (FISH) to evaluate PD-L1 status on a cohort of DLBCL including 94 of DLBCL-NOS, 
      25 of primary mediastinal large B-cell lymphoma (PMBCL) and 7 of double-hit 
      lymphoma (DHL). SP263 with 25% for immune cell (IC) or combined cell and SP142 
      with 10% for tumor cell (TC), 20% for both of IC and combined cell were proved to 
      have corresponding survival prognostic. Combined(+) showed comparable prognostic 
      value with TC(+) and IC(+) . SP263 and SP142 showed strong concordance 
      (k = 0.788) with combined(+) rates of 33.3% (42/126) and 34.9% (44/126), 
      respectively. In DLBCL-NOS, TC(+) by SP263 preferred to non-GCB and immunoblastic 
      variant DLBCL-NOS (P = 0.029 and P = 0.004). Combined(+) (SP263 and SP142) were 
      associated with more than one extranodal site involved (P = 0.006, P = 0.042), 
      higher ECOG PS scores (P = 0.001, P < 0.001), high IPI risk (P = 0.012, 
      P = 0.005), and poor treatment response (P = 0.095, P = 0.002). IC(+) by SP263 
      and SP142 were both independent risk factors (P = 0.027, P = 0.037). 9p24.1 locus 
      amplification and gain were identified in 4.3% and 7.6% DLBCL-NOS and indicated 
      shorter overall survival (P = 0.004). Positive rate of PD-L1 by RNAscope was 
      36.5%, while no clinical significance shown. PD-L1 positive rates were all higher 
      in PMBCL and DHL than in DLBCL-NOS by SP263, SP142, RNAscope, and FISH 
      (P = 0.001, P < 0.001, P = 0.005 and P < 0.001, respectively). In conclusion, 
      combined PD-L1 expression by IHC was potentially reliable and convenient as a 
      predicting biomarker. SP263 staining was easier to evaluate and recognized more 
      PD-L1-stained cells, but SP142 presented a better prognostic indicator. FISH and 
      RNAscope could be used as supplementary assays. PMBCL itself was a sensitive 
      cohort for immunotherapy.
CI  - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Huang, Sixia
AU  - Huang S
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Nong, Lin
AU  - Nong L
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Liang, Li
AU  - Liang L
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Zheng, Yalin
AU  - Zheng Y
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Liu, Jumei
AU  - Liu J
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Li, Dong
AU  - Li D
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Pathology, Peking University Health Science Center, Beijing, China.
FAU - Li, Ting
AU  - Li T
AUID- ORCID: 0000-0002-1497-3888
AD  - Department of Pathology, Peking University First Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190531
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
SB  - IM
MH  - B7-H1 Antigen/genetics/*metabolism
MH  - *Biomarkers, Tumor
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Expression
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/genetics/*metabolism/mortality
MH  - Male
MH  - Neoplasm Staging
MH  - Prognosis
PMC - PMC6639200
OTO - NOTNLM
OT  - DLBCL
OT  - FISH
OT  - IHC
OT  - PMBCL
OT  - RNAscope
COIS- No conflict of interest disclaimed.
EDAT- 2019/06/01 06:00
MHDA- 2020/08/04 06:00
PMCR- 2019/05/31
CRDT- 2019/06/01 06:00
PHST- 2019/01/16 00:00 [received]
PHST- 2019/04/29 00:00 [revised]
PHST- 2019/05/16 00:00 [accepted]
PHST- 2019/06/01 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2019/06/01 06:00 [entrez]
PHST- 2019/05/31 00:00 [pmc-release]
AID - CAM42316 [pii]
AID - 10.1002/cam4.2316 [doi]
PST - ppublish
SO  - Cancer Med. 2019 Jul;8(8):3831-3845. doi: 10.1002/cam4.2316. Epub 2019 May 31.